1/ We Diagnose Earlier
We identify signals of depression and neurodegeneration up to 10–15 years before symptoms appear. Early detection helps prevent chronic disease, slow progression, and protect long-term quality of life.
2/ We Measure Treatment Response
Ranvier measures how the body reacts to treatment - in real time. A change in taste perception after the first dose can act as a powerful early indicator of whether a therapy is likely to work. This has never been done before.
3/ We Individualise Medicines
Our unique protein biomarkers guide doctors in tailoring to each individual - matching the interventions at cellular level with a high degree of confidence.
Depression is the most misdiagnosed and undertreated health condition in the world. It affects over 300 million people and is often the first clinical sign of deeper neurological issues such as Alzheimer’s and Parkinson’s. Yet most diagnoses still rely on outdated questionnaires and subjective self-reporting. This gap leaves millions of people without answers or access to timely care. The world needs a new standard for speed, accuracy, and objectivity in mental health. Ranvier is building that standard.
Real progress demands open thinking and honest critique. At Ranvier, we amplify voices from across neuroscience, technology, clinical care, and health policy. These experts challenge outdated models and offer fresh insight into what needs to change—so that diagnosis, treatment, and equity keep pace with science.
